Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Generation Bio raises $125 million
by Ryan Cross
March 5, 2018
| A version of this story appeared in
Volume 96, Issue 10
Less than two months after launching with $25 million in series A funding, Generation Bio has raised $100 million in series B funding to develop its re-doseable gene therapies. Existing gene therapies require DNA to be delivered into cells via a virus, which means a therapy can’t be given to the same person twice because it will cause an immune response. Generation Bio is developing a nonviral approach that uses lipid nanoparticles to deliver a strand of close-ended DNA. The Cambridge, Mass.-based firm was founded by Atlas Venture.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter